Pcn125 - First Insights Into Comparing Expenditures for Targeted Therapy and Survival in NSCLC

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.208
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

First Insights Into Non-Invasive Administration Routes for Non-Viral Gene Therapy

2015English

Comparing State-Only Expenditures for AIDS.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1988English

Expanding Targeted Therapies for NSCLC

Cancer Discovery
Oncology
2014English

Association of First-In-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

JAMA Oncology
Cancer ResearchOncology
2018English

Denosumab for Bone Diseases: Translating Bone Biology Into Targeted Therapy

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2011English

Translating Molecular Insights in Autoimmunity Into Effective Therapy

Annual Review of Immunology
AllergyImmunology
2009English

P3.01-65 First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients With EGFR-Mutant Metastatic NSCLC Receiving TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Insights Into Deoxyribonucleoside Therapy for Mitochondrial TK2 Deficient mtDNA Depletion

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Insights Into the Roles of Midazolam in Cancer Therapy

Evidence-based Complementary and Alternative Medicine
Alternative MedicineComplementary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy